Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B | NEJM
Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections - Ramesh - 2021 - ChemMedChem - Wiley Online Library
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine | Scientific Reports
Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B
Entekor 0.5 Tablets, Treatment: Hepatitis B
Entecavir - wikidoc
The Effects of Nucleoside/Nucleotide Analogues on Host Immune Cells: The Baseline for Future Immune Therapy for HBV? - Lauke L Boeijen, Michelle Spaan, André Boonstra, 2020
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance | Semantic Scholar
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/mL oral solution, Baraclude® SMC No. (747/11) Bristol-Myers Squibb
Entecavir | C12H15N5O3 | CID 135398508 - PubChem
Lipophilic Triphosphate Prodrugs of Various Nucleoside Analogues | Journal of Medicinal Chemistry
Entecavir Tablets 0.5mg
Original Article Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients na
Molecules | Free Full-Text | Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents
INTRODUCTION
Adverse effects of oral antiviral therapy in chronic hepatitis B
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19 | Journal of Proteome Research
HBV Nucleoside/Nucleotide Analogues in Various Stages of Clinical... | Download Table